Contact
16 Jan 26
News
16 Jan 26

Biocomposites named in The Sunday Times 100 Tech 2026

Keele, 16 January 2026 – Biocomposites has been named in the 2026 edition of The Sunday Times 100 Tech – the definitive ranking of Britain’s fastest-growing private technology companies.

This recognition highlights our continued commitment to innovation in infection management and reflects the hard work of our incredible team in delivering transformative solutions for patients worldwide.

The full list is now live – explore it here.

Thank you to everyone who has contributed to this achievement – we’re excited to keep pushing boundaries in MedTech and beyond!

Contact for Media enquiries

Optimum Strategic Communications

Mary Clark, Stephen Adams, Katie Flint, Nellie Stephens
Tel: +44 (0)20 3922 1906
biocomposites@optimumcomms.com

About Biocomposites

Biocomposites is an international medical device company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue. Based in Keele, UK, it has global operations across Europe, South America, USA, Canada, China and India. Biocomposites is a world leader in the development of innovative calcium compounds and bone cements for surgical use. Its products regenerate bone and target infection risks across a variety of specialties, including musculoskeletal infection, orthopaedics, trauma, spine, foot and ankle, podiatry and sports injuries. Biocomposites’ products are now used in over 1 million procedures per annum and sold in more than 100 countries around the world. In January 2026 Biocomposites was named as one of the UK’s 100 fastest growing technology companies by The Sunday Times. See here for The Sunday Times’ 100 Tech 2026 list. Please visit biocomposites.com to learn more.

About SYNICEMTM bone cements

SYNICEMTM bone cements have been developed to provide the ideal interface between prosthesis and bone – optimised to provide secure and stable fixation for joint replacement surgery, including between irregular bone surfaces and the prosthesis. SYNICEMTM bone cements are manufactured in-house under strictly controlled conditions using out proprietary process. The SYNICEMTM bone cement range includes cements loaded with gentamicin (an antibiotic) for revision procedures in patients at high risk of infection due to gentamicin-sensitive bacteria and patients with compromised immunity. SYNICEMTM bone cements are already used in more than 100 countries around the world.

Other news

Listed below is a list of the 4 most recent news updates made by Biocomposties


Visit our News & Events page

Library

Interested in other types of our content? See a list of some of our most recent below.

Explore Library